Kura Oncology Statistics
Total Valuation
Kura Oncology has a market cap or net worth of $1.57 billion. The enterprise value is $1.06 billion.
Market Cap | 1.57B |
Enterprise Value | 1.06B |
Important Dates
The last earnings date was Thursday, May 2, 2024, after market close.
Earnings Date | May 2, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Kura Oncology has 76.18 million shares outstanding. The number of shares has increased by 22.66% in one year.
Shares Outstanding | 76.18M |
Shares Change (YoY) | +22.66% |
Shares Change (QoQ) | +8.43% |
Owned by Insiders (%) | 1.07% |
Owned by Institutions (%) | 108.97% |
Float | 48.62M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 3.11 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.67, with a Debt / Equity ratio of 0.03.
Current Ratio | 16.67 |
Quick Ratio | n/a |
Debt / Equity | 0.03 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -105.18 |
Financial Efficiency
Return on equity (ROE) is -37.50% and return on invested capital (ROIC) is -35.19%.
Return on Equity (ROE) | -37.50% |
Return on Assets (ROA) | -34.10% |
Return on Capital (ROIC) | -35.19% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.18M |
Employee Count | 142 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +54.73% in the last 52 weeks. The beta is 0.89, so Kura Oncology's price volatility has been lower than the market average.
Beta (1Y) | 0.89 |
52-Week Price Change | +54.73% |
50-Day Moving Average | 20.45 |
200-Day Moving Average | 15.08 |
Relative Strength Index (RSI) | 46.96 |
Average Volume (30 Days) | 836,944 |
Short Selling Information
The latest short interest is 10.31 million, so 13.53% of the outstanding shares have been sold short.
Short Interest | 10.31M |
Short Previous Month | 10.35M |
Short % of Shares Out | 13.53% |
Short % of Float | 21.21% |
Short Ratio (days to cover) | 12.91 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -183.69M |
Pretax Income | -168.09M |
Net Income | -168.09M |
EBITDA | -165.63M |
EBIT | -166.50M |
Earnings Per Share (EPS) | -$2.17 |
Balance Sheet
The company has $527.12 million in cash and $16.97 million in debt, giving a net cash position of $510.15 million or $6.70 per share.
Cash & Cash Equivalents | 527.12M |
Total Debt | 16.97M |
Net Cash | 510.15M |
Net Cash Per Share | $6.70 |
Equity / Book Value | 505.08M |
Book Value Per Share | 6.63 |
Working Capital | 505.57M |
Cash Flow
In the last 12 months, operating cash flow was -$137.80 million and capital expenditures -$216,000, giving a free cash flow of -$138.01 million.
Operating Cash Flow | -137.80M |
Capital Expenditures | -216,000 |
Free Cash Flow | -138.01M |
FCF Per Share | -$1.65 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Kura Oncology does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -22.66% |
Shareholder Yield | -22.66% |
Earnings Yield | -10.71% |
FCF Yield | -8.79% |
Analyst Forecast
The average price target for Kura Oncology is $27.94, which is 35.57% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $27.94 |
Price Target Difference | 35.57% |
Analyst Consensus | Strong Buy |
Analyst Count | 8 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -40.47% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |